IntelGenx Announces Director Election Voting Results

SAINT LAURENT, Quebec, May 08, 2024 (GLOBE NEWSWIRE) — IntelGenx Technologies Corp. (TSX: IGX) (OTCQB: IGXT) (the “Business” Or “IntelGenx“) announces that, at the annual meeting of shareholders of the Company held on May 7, 2024 (the “Annual meeting“), the shareholders voted in favor of all the points proposed by the Company, including the election of directors by a majority of the votes cast by the shareholders present or represented by proxy.

The Annual Meeting was held in a virtual format only, for those who were shareholders of the Company at the close of business on March 11, 2024 (the “Registration Date“), in accordance with the notices and proxies duly communicated to them. As of the record date, there were 174,658,096 shares of the Company’s common stock outstanding at a par value of $0.00001 (the “IntelGenx Common Stock“). As of the record date, shareholders holding 109,675,659 shares (62,794%) of IntelGenx common stock were present at the annual meeting or by proxy. Each of these shareholders was entitled to one vote for each share of IntelGenx common stock held as of the record date.

During the General Meeting, the following questions were put to the vote of the Company’s shareholders:

The detailed voting results for the election of directors are as follows:

About IntelGenx

IntelGenx is a leading drug delivery company focused on the development and manufacturing of pharmaceutical films.

Superior cinema technologies from IntelGenx, including VersaFilm^®DisinteQ^™VetaFilm^® and VevaDerm transdermal^™, enable the creation of next-generation pharmaceutical products that address unmet medical needs. IntelGenx’s portfolio of innovative products provides significant benefits to patients and physicians for numerous therapeutic conditions.

IntelGenx’s highly skilled team provides comprehensive pharmaceutical services to pharmaceutical partners, including R&D, analytical method development, clinical monitoring, intellectual property and regulatory services. IntelGenx’s state-of-the-art manufacturing facility offers full service, providing lab-scale production through to pilot and commercial scale. For more information, visit www.intelgenx.com.

The story continues

Forward-looking information and statements

This document may contain forward-looking information about IntelGenx’s operating results and business prospects that involve significant risks and uncertainties. Statements that are not purely historical are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements include, without limitation, statements about IntelGenx’s plans, objectives, expectations, strategies, intentions or other characterizations of future events or circumstances and are generally identified by the words “may”, “will”. expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates,” “could,” “would” and similar expressions. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. Because these forward-looking statements are subject to a number of risks and uncertainties, IntelGenx’s actual results could differ materially from those expressed or implied by these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed under the caption “Risk Factors” in IntelGenx’s Annual Report on Form 10-K, filed with the Securities and Exchange Commission. of the United States and available at www. sec.gov, and also filed with Canadian securities regulators at www.sedarplus.com. IntelGenx undertakes no obligation to update these forward-looking statements.

Source: IntelGenx Technologies Corp.

For more information please contact:

Stephen Kilmer
Investor Relations
(514) 331-7440 ext. 232
[email protected]

Or

Ingrid Zerbe
Corporate Secretary
IntelGenx Technologies Corp.
[email protected]